Johnson & Johnson's Janssen Has Submitted A Supplemental Marketing Application To The European Medicines Agency For Rybrevant (Amivantamab) In Combination With Chemotherapy For Advanced Non-small Cell Lung Cancer With EGFR Exon 20 Insertion Mutations
Portfolio Pulse from Benzinga Newsdesk
Johnson & Johnson's Janssen has submitted a supplemental marketing application to the European Medicines Agency for Rybrevant (Amivantamab) in combination with chemotherapy for advanced non-small cell lung cancer with EGFR Exon 20 insertion mutations.
October 06, 2023 | 12:13 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Johnson & Johnson's Janssen has submitted a supplemental marketing application for Rybrevant in combination with chemotherapy for advanced non-small cell lung cancer to the European Medicines Agency. This could potentially expand the market for Rybrevant.
The submission of a supplemental marketing application for Rybrevant to the European Medicines Agency indicates that Johnson & Johnson is seeking to expand the market for this drug. If approved, this could potentially increase the company's revenues and positively impact its stock price in the short term.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100